The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C

Kidney International

Volumn 78, Issue 1, 2010, Pages 103-109

  Liu, Chen Hua ^a   Liang, Cheng Chao ^b   Liu, Chun Jen ^a   Hsu, Shih Jer ^a   Lin, Jou Wei ^a   Chen, Shih I ^a   Hung, Peir Haur ^c   Tsai, Hung Bin ^d   Lai, Ming Yang ^a   Chen, Pei Jer ^a   Chen, Jun Herng ^a   Chen, Ding Shinn ^a   Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Aspartate aminotransferase to platelet ratio index; Chronic hepatitis C; Hemodialysis; Liver biopsy; Noninvasive

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; BIOPSY; COMPLICATION; DIAGNOSTIC USE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; RENAL REPLACEMENT THERAPY; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOPSY; BIOPSY, NEEDLE; BLOOD PLATELETS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; RENAL DIALYSIS; TRANSAMINASES;

EID: 77953655149     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.74     Document Type: Article

References (26)

1. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.
2. Nakayama E, Akiba T, Marumo F et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
3. Fabrizi F, Martin P, Dixit V et al. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-1277.
4. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
5. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
6. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S152-S160.
7. Liu CH, Liang CC, Lin JW et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-530.
8. Liu CH, Liang CC, Liu CJ et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009; 58: 314-316.
9. Fabrizi F, Dixit V, Messa P et al. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008; 15: 79-88.
10. Gordon CE, Uhlig K, Lau J et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-277.
11. Ozgür O, acioqlu S et al. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 1996; 74: 442-443.
12. Pawa S, Ehrinpreis M, Mutchnick M et al. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007; 5: 1316-1320.
13. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322.
14. Gangji AS, Sohal AS, Treleaven D et al. Bleeding in patients with renal insufficiency: a practical guide to clinical management. Thromb Res 2006; 118: 423-428.
15. Cotler SJ, Diaz G, Gundlapalli S et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191-195.
16. Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525.
17. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457. (Pubitemid 37466971)
18. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
19. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-921.
20. Leroy V, Hilleret MN, Sturm N et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775-782.
21. Schiavon LL, Schiavon JL, Filho RJ et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46: 307-314.
22. Gür G, Yilmaz U et al. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc 2004; 36: 50-52.
23. Sterling RK, Sanyal AJ, Luketic VA et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 3576-3582.
24. Liu CH, Lin JW, Tsai FC et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006; 26: 1087-1094.
25. Poynard T, Halfon P, Castera L et al. FibroPaca Group. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalence of fibrosis stages. Clin Chem 2007; 53: 1615-1622.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.